Skip to main content
Loading

Selection of the optimal linker for highly hydrophobic payloads

09 Feb 2027
ADC Linker Design & Conjugation Technologies
  • How is the ADC space continuing to grow, and why does it remain heavily focused on similar payload types?
  • Which different payloads may have greater potential for patients who do not respond to established TOPOi and tubulin inhibitor ADCs?
  • What new approaches are in preclinical and early clinical development, including new cytotoxics and inhibitors, degrader-antibody conjugates, and radionuclides?
  • Why has consensus not yet emerged on the key areas of focus and the best ways to identify promising new candidates?
Industry Expert
Julia Gavrilyuk, VP & Head of ADC Technology Development - Adcytherix